Arbutus Biopharma Appoints Tram Tran, M.D. to its Board of Directors
11 nov. 2021 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting®
10 nov. 2021 16h30 HE
|
Arbutus Biopharma Corporation
Arbutus’ Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B HBsAg remains suppressed up to 28 weeks after discontinuation of AB-729 ...
Arbutus to Participate at Jefferies London Healthcare Conference
10 nov. 2021 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update
04 nov. 2021 07h30 HE
|
Arbutus Biopharma Corporation
On-track for multiple data readouts of AB-729 and AB-836 in Q4 2021 First patient dosed in Phase 2a clinical trial combining AB-729, Peg-IFNα-2a and nucleos(t)ide analog (“NA”) therapy ...
Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021
01 nov. 2021 16h05 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update
21 oct. 2021 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus to Participate in October Investor Conferences
28 sept. 2021 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
21 sept. 2021 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress™ 2021 - All Selected for Best of ILC™
26 juin 2021 07h15 HE
|
Arbutus Biopharma Corporation
AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks AB-729 resulted in HBsAg declines below 100 IU/ml in 75%...
Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June
02 juin 2021 07h30 HE
|
Arbutus Biopharma Corporation
Conference Call and Webcast to discuss the new data being presented at EASL scheduled for 8:00 AM ET, Monday, June 28, 2021 WARMINSTER, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma...